Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

BACKGROUND: We have recently described the correlation between quantitative measures of HER2 expression or HER2 homodimers by the HERmark assay and objective response (RR), time-to progression (TTP), and overall survival (OS) in an expanded access cohort of trastuzumab-treated HER2-positive patients...

詳細記述

保存先:
書誌詳細
主要な著者: Toi, Masakazu, Sperinde, Jeff, Huang, Weidong, Saji, Shigehira, Winslow, John, Jin, Xueguang, Tan, Yuping, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Aogi, Kenjiro, Morita, Satoshi, Petropoulos, Christos, Bates, Michael
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2010
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837013/
https://ncbi.nlm.nih.gov/pubmed/20178580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-56
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料